跳至主要内容
临床试验/EUCTR2021-001554-61-NO
EUCTR2021-001554-61-NO进行中(未招募)1 期

Anti-Coagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation (ACASA-TAVI) - ACASA-TAVI

Oslo University Hospital0 个研究点目标入组 360 人开始时间: 2021年6月1日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patients with aortic stenosis who are accepted for transcatheter aortic valve implantation by the heart team and are less than 80 years old at the time of the procedure.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 360

排除标准

  • - Any clinical indication for either anticoagulation (atrial fibrillation, venous thrombosis) or antiplatelet drug (recent percutaneous coronary intervention, etc)
  • - Any contraindication for either anticoagulation or antiplatelet drugs
  • - Failure to provide signed consent
  • - Unable to start study medication within 72 hours
  • - Overt cognitive impairment

研究者

发起方
Oslo University Hospital

相似试验